An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir.

Eva Agnes Odongpiny LakerMaria Sarah NabaggalaArvind KaimalDamalie NalwangaBarbara CastelnuovoAbdu MusubireAgnes KiraggaMohammed LamordeRosalind Parkes- Ratanshi

Published in: BMC infectious diseases (2019)

Patients using the WHO recommended second-line of boosted atazanavir have comparable virological suppression to those on boosted lopinavir.

Keyphrases

end stage renal disease
hiv infected patients
ejection fraction
chronic kidney disease
newly diagnosed
antiretroviral therapy
hiv infected
prognostic factors
peritoneal dialysis
type diabetes
hiv aids
metabolic syndrome
hepatitis c virus
insulin resistance
weight loss